Cholesteryl ester transfer protein (CETP) inhibitors, such as anacetrapib, increase HDL cholesterol levels.56,57 The REVEAL trial demonstrated that treatment with anacetrapib reduced the risk of a composite cardiovascular disease endpoint, though the impact of CETP inhibition on ischemic stroke risk remains uncertain.57 To investigate this question, Georgakis et al. The gene discussed is CETP; the disease is cardiovascular disorder.